Avonib is a type 1 isocitrate dehydrogenase (IDH1) inhibitor that specifically inhibits the mutant form of IDH1 in the cytoplasm, preventing the formation of 2-hydroxyglutarate. AG-120 can induce cell differentiation and inhibit the proliferation of tumor cells expressing IDH1.